The platform
De-risk your pipeline: discard unsafe molecules early on with human QT
How it works
1
Input heart ion channel measurements
of your candidates
2
Predict human QT prolongation
and arrhythmic cases
3
Compare, identify and
discard unsafe candidates
Key benefits
Exploit the benefits of full heart simulations.
Use QT predictions based on full heart simulations to anticipate the risk of your compounds at an early stage and decide which candidates are worth further exploration.
Characterize compounds using ion channel IC50 - H measurements or through probability distributions and explore all possible combinations.
Account for environmental shifts by toggling between saline buffer and plasma measurements.
Get accurate predictions for the whole concentration space around your target concentration and different protein bindings.
Study edge cases such as accidental or intentional drug abuse.
Understand the risk profile of your compounds through a sex-specific analysis of the QT prolongation and arrhythmia predictions for all channel measurement combinations, accounting for sex-based variability.
Avoid changing the study model between pipeline stages. Simulate your promising compounds with V.HEART Trials to get granular around different populations of virtual hearts.
Configure trials
Simulate & Postprocess
Analyse results
What we offer
First arrhythmic cases
Combinations that produce min/max ΔQT
QT response analysis by sex
Concentration range for ΔQT of 10ms
How does our technology work?
ELEM’s technology combines patient-specific data, high-performance physics-based simulation, and advanced computational modeling to create Virtual Human Twins.
This enables predictive insights, supporting faster, safer, and data-driven biomedical advancement.
Get started
One of our experts will get in touch with you
